• 2018-07
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • In this study we investigated the contribution


    In this study, we investigated the contribution of GCK, G6PC, and PCK expression to glycemia in diabetes. We examined liver tissue from 40 obese subjects: 12 had normal glucose tolerance (NGT) and 28 had type 2 diabetes.
    Materials and methods
    Discussion This study aimed to investigate contributors to the increase in HGP during diabetes. Consistent with prior reports, we find that liver expression of gluconeogenic gpr40 agonist alone cannot explain this phenotype [5], [6]. On the other hand, our data indicate that suppression of hepatic GCK in diabetes patients: (i) explains the decreased GCK activity observed in previous studies [8], [9], [10], [11], [12], and (ii) contributes to hyperglycemia quantitatively. The fact that defective hepatic GCK is sufficient to impair glycogen synthesis and increase gluconeogenesis was previously established in studies of liver metabolism in MODY2 patients [13]. Moreover, it has been shown that restoration of hepatic GCK activity in Zucker diabetic fatty rats causes normalization of plasma glucose and suppression of endogenous glucose production [14]. GCK is regulated by posttranslational and transcriptional mechanisms [7]. Posttranslational regulation by glucose occurs through the glucokinase regulatory protein, which binds to GCK and causes its nuclear sequestration and protein stabilization. Dissociation of the two proteins occurs at high glucose concentrations, causing cytoplasmic translocation and accelerated degradation of GCK [7], [15]. One of the limitations of our study was the lack of sufficient tissue to perform immunoblots. However, we found compelling evidence that frank diabetes is associated with a disruption in the transcriptional control of GCK, which is carried out by insulin [16]. Major mediators of insulin's effect on GCK are the FOXO transcription factors. FOXOs are known for their role in promoting HGP during fasting [17]. Under normal conditions, FOXOs are inactivated by insulin, through AKT-mediated phosphorylation and nuclear exclusion. Thus, a widely held explanation for excessive glucose production during diabetes is inappropriate activation of the hepatic FOXO pathway, due to insulin resistance. Two critical aspects of how FOXO promotes glucose production are by promoting G6PC [17] and suppressing GCK [18], [19], [20], [21]. This suggests that activated FOXOs may be responsible for excessive GCK suppression in diabetes. Consistent with this possibility, FOXO target IGFBP1 was significantly elevated in the high HbA1c patients (data not shown). How, then, can we reconcile the fact that G6PC was not also elevated? One possible explanation is that FOXOs' effect on GCK is more potent than its effect on G6PC, as we have previously observed in mice [21]. It is also possible that posttranslational modifications of FOXO that are induced by hyperglycemia, such as acetylation, affect some targets more than others [22], [23]. In addition to its role in glucose homeostasis, hepatic GCK also plays a critical role in promoting de novo lipogenesis (DNL), a fact that has hindered the development of glucokinase activators as diabetes therapy [24]. Indeed, previous work has shown that liver GCK expression is positively associated with liver triglyceride content and a marker of DNL in humans [25]. Based on these findings, suppression of GCK – as we observed in our severely diabetic patients – might be expected to reduce lipogenic flux. This may seem paradoxical, as diabetic patients typically demonstrate hypertriglyceridemia. However, we observed no correlation of GCK to plasma triglyceride levels in our subjects (data not shown). A potential explanation is that DNL contributes to only a portion of circulating triglyceride levels [26], [27], [28], the major fraction originating from reesterification of free fatty acids; the latter substrate circulates in increased amounts in type 2 diabetic patients due to insulin resistance of lipolysis [29], [30]. There has been a long-standing interest in developing antidiabetic glucokinase activators [24]. Given the narrow therapeutic window of these molecules, it may be important to increase our understanding of GCK dysregulation in the progression of T2D. This may be particularly valuable in designing individualized therapeutic regimens [4].